APT Neuroscience Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	18,378	20,415	17,563
Revenue Growth (YoY)	-9.98%	16.24%	-
Cost of Revenue	17,779	19,930	19,066
Gross Profit	599.04	485.67	-1,503
Selling, General & Admin	7,344	6,330	2,744
Research & Development	5,063	93.8	-
Other Operating Expenses	221.16	149.57	66.97
Operating Expenses	13,351	7,232	1,629
Operating Income	-12,752	-6,746	-3,133
Interest Expense	-2,778	-3,405	-53.71
Interest & Investment Income	2,763	2,172	327.51
Earnings From Equity Investments	-7,728	-4,736	-
Currency Exchange Gain (Loss)	1.3	251.74	3.62
Other Non Operating Income (Expenses)	1,425	7,955	-1,091
EBT Excluding Unusual Items	-19,070	-4,509	-3,946
Gain (Loss) on Sale of Investments	69.75	87.36	-38.71
Gain (Loss) on Sale of Assets	-18.6	-2.67	-0.04
Other Unusual Items	-	-32.72	-
Pretax Income	-19,018	-4,457	-3,985
Income Tax Expense	148.44	546.14	-737.05
Net Income	-19,167	-5,003	-3,248
Net Income to Common	-19,167	-5,003	-3,248
Shares Outstanding (Basic)	147	122	94
Shares Outstanding (Diluted)	147	122	94
Shares Change (YoY)	20.82%	29.64%	-
EPS (Basic)	-130.00	-41.00	-34.50
EPS (Diluted)	-130.00	-41.00	-35.00
Free Cash Flow	-10,744	-8,708	840.09
Free Cash Flow Per Share	-72.88	-71.35	8.93
Gross Margin	3.26%	2.38%	-8.56%
Operating Margin	-69.39%	-33.05%	-17.84%
Profit Margin	-104.29%	-24.51%	-18.49%
Free Cash Flow Margin	-58.47%	-42.65%	4.78%
EBITDA	-11,588	-6,237	-3,017
EBITDA Margin	-63.06%	-30.55%	-17.18%
D&A For EBITDA	1,164	509.66	115.59
EBIT	-12,752	-6,746	-3,133
EBIT Margin	-69.39%	-33.05%	-17.84%
Advertising Expenses	24.1	60.68	8.6

Source: S&P Global Market Intelligence. Standard template. Financial Sources.